Entresto (sacubitril/valsartan) is prescribed for adults with chronic heart failure and reduced ejection fraction (HFrEF), specifically those with New York Heart Association (NYHA) Class II to IV symptoms. It is used alongside standard therapies such as beta-blockers and ACE inhibitors to improve outcomes.
Entresto works by blocking the angiotensin II receptor and enhancing the activity of natriuretic peptides, which reduce fluid retention and lower blood pressure. This dual mechanism helps protect the heart from further damage and slows disease progression.
The drug was approved by the U.S. Food and Drug Administration (FDA) in 2015 based on results from the Model-HF trial, which showed a 20% reduction in cardiovascular death and a 21% reduction in hospitalization for heart failure compared to enalapril, a standard ACE inhibitor.
Entresto combines two active ingredients: sacubitril and valsartan. Sacubitril inhibits neprilysin, an enzyme that breaks down natriuretic peptides. These peptides promote sodium excretion, vasodilation, and reduced cardiac remodeling. Valsartan blocks the angiotensin II receptor, preventing vasoconstriction and aldosterone release.
This dual action counteracts the harmful effects of the renin-angiotensin-aldosterone system (RAAS) while boosting the beneficial effects of the natriuretic peptide system. The result is improved cardiac function and reduced strain on the heart muscle.
A 2018 analysis published in The Lancet confirmed that Entresto lowers mortality and hospitalization rates across diverse patient groups, including older adults and those with diabetes or prior myocardial infarction.
Entresto is available in three strengths: 24 mg/26 mg, 49 mg/51 mg, and 97 mg/103 mg tablets. The dosage is titrated upward over weeks to reach the target dose of 97/103 mg twice daily, depending on tolerability and renal function.
| Dosage Strength | Sacubitril (mg) | Valsartan (mg) | Typical Starting Dose |
|---|---|---|---|
| 24/26 mg | 24 | 26 | 24/26 mg BID |
| 49/51 mg | 49 | 51 | 49/51 mg BID |
| 97/103 mg | 97 | 103 | 97/103 mg BID |
Patients must switch from ACE inhibitors or ARBs to Entresto under medical supervision due to the risk of angioedema. A washout period of at least 36 hours is required before initiating Entresto.
Entresto is indicated for symptomatic heart failure with reduced ejection fraction (HFrEF), defined as an ejection fraction ≤40%. It is not effective in heart failure with preserved ejection fraction (HFpEF).
In clinical practice, Entresto is typically added to existing therapy after stabilization on beta-blockers, diuretics, and mineralocorticoid receptor antagonists. It is not a first-line agent but a guideline-recommended addition for eligible patients.
A real-world study from 2021 using Medicare data found that patients who initiated Entresto had a 32% lower risk of all-cause mortality over 18 months compared to those continuing on ACE inhibitors or ARBs.
Entresto is often mistaken for a generic version of enalapril or other ACE inhibitors due to similar indications. However, it is not interchangeable with ACE inhibitors or ARBs. Patients who were previously on an ACE inhibitor must wait at least 36 hours before starting Entresto to avoid the risk of angioedema.
Another common error is assuming Entresto treats hypertension alone. While it lowers blood pressure, it is not approved for isolated hypertension. Its primary purpose is to reduce morbidity and mortality in HFrEF.
One non-obvious fact: Entresto is the first drug shown to outperform an ACE inhibitor in a large-scale outcome trial. This marked a shift in heart failure management, leading to updated guidelines recommending Entresto as preferred therapy over ACE inhibitors in eligible patients.
A 68-year-old man with a history of myocardial infarction and an ejection fraction of 32% presented with NYHA Class III symptoms. He was on metoprolol succinate 100 mg daily, furosemide 40 mg twice daily, and spironolactone 25 mg daily. His blood pressure was 130/80 mmHg, and serum creatinine was 1.3 mg/dL.
After discontinuing his ACE inhibitor (lisinopril) and waiting 36 hours, he was started on Entresto 24/26 mg twice daily. Over six weeks, the dose was increased to 97/103 mg twice daily. After three months, his symptoms improved from NYHA Class III to Class II, and his ejection fraction improved to 38%.
His follow-up echocardiogram showed reduced left ventricular end-diastolic diameter and improved global longitudinal strain, indicating structural improvement in cardiac function.
My experience treating patients with Entresto confirms that consistent titration and monitoring are essential. One patient developed hypotension during dose escalation and required temporary reduction. Close follow-up prevented complications.
Entresto is not a diuretic, nor does it directly reduce fluid overload. Diuretics remain necessary for symptom control. Entresto addresses underlying neurohormonal activation, not volume status.
It is also not suitable for patients with severe renal impairment (eGFR <30 mL/min/1.73m²) or hyperkalemia. Concomitant use with potassium-sparing agents requires caution.
According to the American College of Cardiology (ACC) and American Heart Association (AHA) guidelines, Entresto should be considered for all patients with HFrEF who are stable on optimal therapy, regardless of age or comorbidity burden.
Entresto is prescribed for heart failure with reduced ejection fraction to improve survival and reduce hospitalizations. It is not used for hypertension alone or HFpEF. Its dual-action design offers superior outcomes compared to older therapies.